Your session is about to expire
← Back to Search
Other
Orforglipron for Obesity (ATTAIN-1 Trial)
Phase 3
Recruiting
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 72
Awards & highlights
ATTAIN-1 Trial Summary
This trial will explore if a new pill can help adults with obesity or overweight and related health issues.
Who is the study for?
This trial is for adults with obesity or overweight who also have weight-related health issues like high blood pressure, sleep apnea, heart disease, or high cholesterol. Participants should have a BMI of 30 or higher and a history of unsuccessful dieting to lose weight.Check my eligibility
What is being tested?
The study is testing Orforglipron, an oral medication taken once daily, against a placebo to see if it's effective and safe in helping people with obesity or overweight reduce their body weight.See study design
What are the potential side effects?
While the specific side effects are not listed here, common side effects for weight loss drugs can include digestive issues such as nausea and constipation, headaches, dizziness, dry mouth, and potential changes in mood.
ATTAIN-1 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, week 72
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 72
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Mean Percent Change from Baseline in Body Weight
Secondary outcome measures
Mean Change from Baseline in Diastolic Blood Pressure (DBP)
Mean Change from Baseline in Fasting Glucose
Mean Change from Baseline in Hemoglobin A1c (HbA1c) %
+6 moreATTAIN-1 Trial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: Orforglipron Dose 3Experimental Treatment1 Intervention
Participant will receive orforglipron administered orally.
Group II: Orforglipron Dose 2Experimental Treatment1 Intervention
Participant will receive orforglipron administered orally.
Group III: Orforglipron Dose 1Experimental Treatment1 Intervention
Participant will receive orforglipron administered orally.
Group IV: PlaceboPlacebo Group1 Intervention
Participants will be given placebo.
Find a Location
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor
2,623 Previous Clinical Trials
3,213,979 Total Patients Enrolled
55 Trials studying Obesity
48,219 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,349 Previous Clinical Trials
412,882 Total Patients Enrolled
38 Trials studying Obesity
27,938 Patients Enrolled for Obesity
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have high blood pressure, cholesterol issues, sleep apnea, or heart disease.
Research Study Groups:
This trial has the following groups:- Group 1: Orforglipron Dose 1
- Group 2: Orforglipron Dose 2
- Group 3: Orforglipron Dose 3
- Group 4: Placebo
Awards:
This trial has 1 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Obesity Patient Testimony for trial: Trial Name: NCT05869903 — Phase 3
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Has Orforglipron Dose 1 been granted regulatory approval by the FDA?
"Our team at Power has judged Orforglipron Dose 1's safety to be a 3 due to the existence of both efficacy data and multiple confirmations of its security."
Answered by AI
Are there still opportunities for patients to participate in this research?
"The information on clinicaltrials.gov indicates that this particular trial is not actively recruiting anymore, having been initially posted in June of 2023 and last updated in May of the same year. However, 1194 other medical studies are presently accepting enrolment from patients."
Answered by AI
What is the current count of hospitals engaged in this research endeavor?
"This trial is enrolling participants from a range of medical centres, including the Clinical Research Institute of Arizona (CRI) - Sun City West in Sun City West, John Muir Physician Network Research Center located in Concord and AMCR Institute situated in Escondido. 134 locations are participating overall."
Answered by AI
Who else is applying?
What state do they live in?
Kansas
New York
Other
Texas
What site did they apply to?
Clinical Research Institute of Arizona (CRI) - Sun City West
The Institute for Liver Health dba Arizona Clinical Trials
Intend Research, LLC
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
2
3+
0
Why did patients apply to this trial?
I want a better outcome. Struggle with weight loss. I’m ready to start working on me.
PatientReceived 2+ prior treatments
I'm over weight and live in Houston Tx. I am obese and am hoping I can get some help.
PatientReceived 2+ prior treatments
What questions have other patients asked about this trial?
Is there any fastig? How long do screenings take? What is the screening criteria?
PatientReceived 1 prior treatment
What is the compensation for this trial? How soon until a decision is made if I qualify?
PatientReceived 2+ prior treatments
How responsive is this trial?
Typically responds via
Email
Most responsive sites:
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division: < 48 hours
Average response time
- < 2 Days
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger